MCRB Seres Therapeutics Inc

USD 0.77 -0.01 -0.781851
Icon

Seres Therapeutics Inc (MCRB) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Under-perform

Average Analyst
Rating
stockTargetAdvisor

Under-perform

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.7741

-0.01 (-0.78)%

USD 0.12B

3.02M

USD 2.45(+216.50%)

N/A

Icon

MCRB

Seres Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 0.77
0.00 0
Take a Tour
stockTargetAdvisor

Under-perform

Average Analyst
Rating
stockTargetAdvisor

Under-perform

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.12B

N/A

USD 0.77

Seres Therapeutics Inc (MCRB) Stock Forecast

Show ratings and price targets of :
USD 2.45
(+216.50%)

Based on the Seres Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Seres Therapeutics Inc is USD 2.45 over the next 12 months. Seres Therapeutics Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Seres Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Seres Therapeutics Inc’s stock price was USD 0.7741. Seres Therapeutics Inc’s stock price has changed by -2.67% over the past week, -32.69% over the past month and -86.05% over the last year.

No recent analyst target price found for Seres Therapeutics Inc
No recent average analyst rating found for Seres Therapeutics Inc

Company Overview Seres Therapeutics Inc

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the...Read More

101 Cambridgepark Drive, Cambridge, MA, United States, 02140

233

December

USD

USA

Adjusted Closing Price for Seres Therapeutics Inc (MCRB)

Loading...

Unadjusted Closing Price for Seres Therapeutics Inc (MCRB)

Loading...

Share Trading Volume for Seres Therapeutics Inc Shares

Loading...

Compare Performance of Seres Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for MCRB

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Seres Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.69 (+0.17%) USD107.38B 29.93 21.06

ETFs Containing MCRB

Symbol Name MCRB's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Seres Therapeutics Inc (MCRB) Stock

Based on ratings from 2 analysts Seres Therapeutics Inc's stock is Under-perform. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, 2 sell and hold ratings.

Unfortunately we do not have enough data on MCRB's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for MCRB is USD 2.45 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 1.1.

Unfortunately we do not have enough data on MCRB's stock to indicate if its overvalued.

The last closing price of MCRB's stock was USD 0.77.

The most recent market capitalization for MCRB is USD 0.12B.

Based on targets from 2 analysts, the average taret price for MCRB is projected at USD 2.45 over the next 12 months. This means that MCRB's stock price may go up by +216.50% over the next 12 months.

We can't find any ETFs which contains Seres Therapeutics Inc's stock.

As per our most recent records Seres Therapeutics Inc has 233 Employees.

Seres Therapeutics Inc's registered address is 101 Cambridgepark Drive, Cambridge, MA, United States, 02140. You can get more information about it from Seres Therapeutics Inc's website at https://www.serestherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...